Author:
Sakai Yasuyuki,Shindo Tetsuya,Sato Shunsuke,Takahashi Atsushi,Kunishima Yasuharu,Kato Ryuichi,Itoh Naoki,Okada Manabu,Tachiki Hitoshi,Taguchi Keisuke,Takayanagi Akio,Hotta Hiroshi,Horita Hiroki,Matsukawa Masanori,Matsuki Masahiro,Nishiyama Koyo,Miyazaki Akihiro,Hashimoto Kohei,Tanaka Toshiaki,Masumori Naoya
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism
Reference33 articles.
1. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial––the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150–3157
2. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092
3. NCCN Guideline on Prostate Cancer, Version 2. 2020. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. (Accessed 28 Sept 2020)
4. Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379–382
5. Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, Furukawa TA (2017) Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget 8:68890–68898